Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | STK4 | Q13043 | 1/20 | 0.38 |
| ▸ | STK3 | Q13188 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773845 | 0.86 | TNKS (0.40) | SMN1; SMN2ENPP2TNKSPARP1PARP2 | |
| SCHEMBL5771670 | 0.84 | KDM5B (0.42) | SMN1; SMN2ENPP2LMNANPC1RAB9A | |
| SCHEMBL5774144 | 0.81 | ENPP2 (0.42) | SMN1; SMN2ENPP2LMNANPC1RAB9A | |
| SCHEMBL5771554 | 0.81 | GRIN2B (0.40) | KMT2AMEN1LMNARAB9AALDH1A1 | |
| SCHEMBL5773586 | 0.81 | MAPT (0.43) | SMN1; SMN2LMNANPC1RAB9AALDH1A1 | |
| SCHEMBL5773615 | 0.79 | RXRA (0.56) | — | |
| SCHEMBL5772977 | 0.75 | VEGFA (0.43) | KMT2AMEN1TP53 | |
| Trifluoroacetic Acid SCHEMBL5776129 | 0.72 | MEN1 (0.50) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL5774842 | 0.71 | TDO2 (0.44) | — | |
| Trifluoroacetic Acid SCHEMBL5773443 | 0.71 | LMNA (0.41) | KMT2AMEN1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | SMN1; SMN2 3383/4885ENPP2 3244/4885TNKS 4694/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | SMN1; SMN2 2449/4885ENPP2 3032/4885TNKS 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.